- Rapid Abstract Session A: Cancers of the Esophagus and Stomach
- Rapid Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
- Rapid Abstract Session C: Cancers of the Colon, Rectum, and Anus
Rapid Abstract Session A: Cancers of the Esophagus and Stomach
Kensei Yamaguchi, Yung-Jue Bang, Satoru Iwasa, et al.
In advanced HER2-positive adenocarcinoma of the gastric or gastroesophageal junction, trastuzumab deruxtecan (T-DXd) continues to have an overall survival benefit and demonstrates a clinically relevant improvement in ORR over standard chemotherapy. The safety profile is good to deal with. More info: NCT03329690.
Zev A. Wainberg, Kohei Shitara, Eric Van Cutsem, et al.
After more than two years of follow-up of first-line therapy, the efficacy and safety results of pembrolizumab or pembrolizumab plus chemotherapy versus chemotherapy in patients with gastric or gastroesophageal junction adenocarcinoma included in KEYNOTE-062 did not differ from the final analysis data. Clinical Trial Information: NCT02494583.
Thierry Andre, David Tougeron, Guillaume Piessen, et al.
Nivolumab plus ipilimumab neoadjuvant is possible: it leads to a high pCR rate in patients with MSI/dMMR-resectable OGA. More info: NCT04006262.
Yu Sunakawa, Ryo Matoba, Toshizo Takayama, et al.
Upon treatment with nivolumab, finding the genus Arthrobacter and determining the fatty acid pathway in the gut microbiome can predict skin toxicities in advanced gastric cancer, and various SNPs may be markers for skin toxicity and diarrhea. More information: UMIN000030850.
Jiafu Ji, Lin Shen, Xiangyu Gao et al.
In treatment-naïve advanced adenocarcinoma of the stomach and gastro-jejunal junction (G/GEJ), AK104 combined with mXELOX/XELOX proved to be a promising and potentially new first-line treatment option. Security was manageable. More info: NCT03852251.
More info about General Sessions, Poster Sessions, Trials in Progress Poster Sessions: please refer to the program guide from ASCO-GI
To attend the presentations, slides etc. you need a paid registration from ASCO. Please refer to ASCO GI’s website.
Rapid Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Tanios S. Bekaii-Saab, Alexander I. Spira, Rona Yaeger, et al.
Well-tolerated monotherapy with adagrasib results in encouraging clinical activity in previously treated pancreatic ductal adenocarcinoma and other GI tumors harboring a KRASG12C mutation. More info: NCT03785249.
Chigusa Morizane, Nozomu Machida, Yoshitaka Honma, et al.
The study results show that both etoposide plus cisplatin and irinotecan plus cisplatin remain equivalent as standard first-line chemotherapy. More information: UMIN000014795
Masafumi Ikeda, Kohei Nakachi, Masaru Konishi, et al.
In contrast to surgery alone, significantly longer survival can be achieved with adjuvant S-1 therapy. This therapy is thus becoming the treatment standard for resected biliary tract cancer. Clinical trial information: UMIN000011688.
Shukui Qin, Zhendong Chen, Weijia Fang, et al.
Consistent with the results from KEYNOTE-224 and KEYNOTE-240, the present study results add to the body of evidence that the use of pembrolizumab as second-line therapy for advanced HCC is warranted. More info: NCT03062358
Qihan Fu, Yiwen Chen, Dabing Huang, et al.
Combined PD-1 blockade may extend the benefit of chemotherapy in PDAC. The study authors reached this conclusion based on their observation that the addition of sintilimab to mFFX significantly improved ORR in patients with advanced PDAC. However, superior overall and progression-free survival was not observed. More info: NCT03977272.
More info about General Sessions, Poster Sessions, Trials in Progress Poster Sessions: please refer to the program guide from ASCO-GI
To attend the presentations, slides etc. you need a paid registration from ASCO. Please refer to ASCO GI’s website.
Rapid Abstract Session C: Cancers of the Colon, Rectum, and Anus
Van K. Morris, Christine Megerdichian Parseghian, Michelle Escano, et al.
The proposed treatment has met its predefined efficacy endpoint. This suggests a role for immunotherapy as a novel combination approach for this specific subpopulation of metastatic CRC in MSS. More info: NCT04017650.
Romain Cohen, Aurelia Meurisse, Thomas Pudlarz, et al.
Follow-up also continues to demonstrate sustained activity in patients with chemoresistant MSI/dMMR-mCRC. Interesting: Re-administration of nivolumab appears to result in additional antitumor activity in patients who develop late resistance after immunotherapy discontinuation. More info: NCT03350126
Jianmin Xu, Weitang Yuan, Taiyuan Li, et al.
Robotic surgery for middle and lower rectal cancer is superior to conventional laparoscopic surgery: it significantly reduced surgical injury, improved oncological radicality, and promoted postoperative recovery. More info: NCT02817126.
Afsaneh Barzi, Nilofer Saba Azad, Yan Yang, et al.
The study did not meet its primary endpoint, although study authors said the median OS was "provocative."More info: NCT03657641.
PD-1 blockade alone for mismatch repair deficient (dMMR) locally advanced rectal cancer.
Melissa Amy Lumish, Jenna L. Cohen, Zsofia Kinga Stadler, et al.
Dostarlimab neoadjuvant is effective and well-tolerated, allowing patients with locally advanced rectal adenocarcinoma with dMMR to avoid chemoradiation and surgery. The study authors thus point to a potential new paradigm for the treatment of dMMR locally advanced rectal cancer. More info: NCT04165772.
Takayuki Yoshino, Maria Di Bartolomeo, Kanwal Pratap Singh Raghav et al.
With longer-term follow-up Trastuzumab deruxtecan (T-DXd; DS-8201) showed promising activity and durability. The safety profile did not differ from previous results; The study authors note that interstitial lung disease remains an important identified risk that needs to be carefully monitored so that intervention can be made if necessary. More info: NCT03384940.
More info about General Sessions, Poster Sessions, Trials in Progress Poster Sessions: please refer to the program guide from ASCO-GI
To attend the presentations, slides etc. you need a paid registration from ASCO. Please refer to ASCO GI’s website.